Covid-19 and Antiviral Drugs Used In Its Treatment

Yıl 2022, Cilt: 2 Sayı: 1, 25 - 29, 25.01.2022

Büşra Yüksel , Yücel Kadıoğlu

Öz

The new coronavirus, the seventh family member of β coronaviruses, entered our lives as 2019-nCoV. The first outbreak was seen in December 2019 in Wuhan, China. It has been reported as a zoonotic disease. 2019-nCoV; causes fatal diseases affecting the lungs, heart, liver and the whole body. 2019-nCoV interacts with ACE-2 and infects epithelial cells, initiating endothelial activation, localized inflammation, tissue damage, and dysregulated cytokine release. Antiviral drugs that selectively bind to viral proteases block the proteolytic cleavage of protein precursors necessary to produce infectious, thereby preventing viral replication. Newly designed antiviral drugs act not on viral entry into host cells but instead by blocking one or more steps of virus replication within the cell. Appropriate analytical methods are required to monitor the precise amount, distribution, metabolism, adsorption and elimination of these drugsand their metabolites in biofluids and tissues. These methods are; The preparation of plasma samples includes protein precipitation (PP), solid phase extraction (SPE), liquid-liquid extraction (LLE), or a combination of two or more of these.

Anahtar Kelimeler

Antiviral drugs, extraction, Sars-Cov-2

Kaynakça

• 1. Malik YA, Properties of Coronavirus and SARS-CoV-2. Malays J Pathol. 2020; 42; 3-11.
• 2. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al, SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. N Engl J Med. 2020; 382; 1177-1179.
• 3. Diriba K, Awulachew E, Getu E, The effect of coronavirus infection (SARS-CoV2, MERS-CoV, and SARS-CoV) during pregnancy and the possibility of vertical maternal-fetal transmission: a systematic review and meta-analysis. Eur J Med Res. 2020; 25; 39.
• 4. Ahn DG, Shin HJ, Kim MH, Lee S, Kim HS, Myoung J, et al, Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19). J Microbiol Biotechnol. 2020; 30; 313-324.
• 5. Shi Y, Wang G, Cai XP, Deng JW, Zheng L, Zhu HH, et al, An overview of COVID-19. J Zhejiang Univ Sci B. 2020; 21; 343-360.
• 6. Higgins V, Sohaei D, Diamandis EP, Prassas I, COVID-19: from an acute to chronic disease? Potential long-term health consequences. Crit Rev Clin Lab Sci. 2021; 58; 297-310.
• 7. Majumder J, Minko T, Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19. Aaps j. 2021; 23; 14.
• 8. Samudrala PK, Kumar P, Choudhary K, Thakur N, Wadekar GS, Dayaramani R, et al, Virology, pathogenesis, diagnosis and in-line treatment of COVID-19. Eur J Pharmacol. 2020; 883; 173375.
• 9. Boretti A, Favipiravir use for SARS CoV-2 infection. Pharmacol Rep. 2020; 72; 1542-1552.
• 10. Joshi S, Parkar J, Ansari A, Vora A, Talwar D, Tiwaskar M, et al, Role of favipiravir in the treatment of COVID-19. Int J Infect Dis. 2021; 102; 501-508.
• 11. Şimşek SY, Ünal S. Antiviral treatment of COVID-19. Turk J Med Sci. 2020; 50; 611-619.
• 12. Lin HXJ, Cho S, Meyyur Aravamudan V, Sanda HY, Palraj R, Molton JS, et al, Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence. Infection. 2021; 49; 401-410.
• 13. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB, Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. Jama. 2020; 323; 1824-1836.
• 14. Wang D, Li Z, Liu Y, An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics. J Infect Public Health. 2020; 13; 1405-1414.
• 15. Bartoli A, Gabrielli F, Alicandro T, Nascimbeni F, Andreone P, COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs. Intern Emerg Med. 2021; 16; 281-308.
• 16. Agarwal S, Agarwal SK, Lopinavir-Ritonavir in SARS-CoV-2 Infection and Drug-Drug Interactions with Cardioactive Medications. Cardiovasc Drugs Ther. 2021; 35; 427-440.
• 17. Lam S, Lombardi A, Ouanounou A, COVID-19: A review of the proposed pharmacological treatments. Eur J Pharmacol. 2020; 886; 173451.
• 18. Yadav AK, Wen S, Xu X, Yu L, Antiviral treatment in COVID-19: which is the most promising?-a narrative review. Ann Palliat Med. 2021; 10; 707-720.
• 19. Kumar S, Goicoechea S, Kumar S, Pearce CM, Durvasula R, Kempaiah P, et al, Oseltamivir analogs with potent anti-influenza virus activity. Drug Discov Today. 2020; 25; 1389-1402.
• 20. Acquavia MA, Foti L, Pascale R, Nicolò A, Brancaleone V, Cataldi TRI, et al, Detection and quantification of Covid-19 antiviral drugs in biological fluids and tissues. Talanta. 2021; 224; 121862.
• 21. Collimore WA, Bent GA, A newly modified QuEChERS method for the analysis of organochlorine and organophosphate pesticide residues in fruits and vegetables. Environ Monit Assess. 2020; 192; 128.